Literature DB >> 26224810

Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve.

Rihab Bouchareb1, Ablajan Mahmut1, Mohamed Jalloul Nsaibia1, Marie-Chloé Boulanger1, Abdellaziz Dahou1, Jamie-Lee Lépine1, Marie-Hélène Laflamme1, Fayez Hadji1, Christian Couture1, Sylvain Trahan1, Sylvain Pagé1, Yohan Bossé1, Philippe Pibarot1, Corey A Scipione1, Rocco Romagnuolo1, Marlys L Koschinsky1, Benoît J Arsenault1, André Marette1, Patrick Mathieu2.   

Abstract

BACKGROUND: Mendelian randomization studies have highlighted that lipoprotein(a) [Lp(a)] was associated with calcific aortic valve disease (CAVD). Lp(a) transports oxidized phospholipids with a high content in lysophosphatidylcholine. Autotaxin (ATX) transforms lysophosphatidylcholine into lysophosphatidic acid. We hypothesized that ATX-lysophosphatidic acid could promote inflammation/mineralization of the aortic valve. METHODS AND
RESULTS: We have documented the expression of ATX in control and mineralized aortic valves. By using different approaches, we have also investigated the role of ATX-lysophosphatidic acid in the mineralization of isolated valve interstitial cells and in a mouse model of CAVD. Enzyme-specific ATX activity was elevated by 60% in mineralized aortic valves in comparison with control valves. Immunohistochemistry studies showed a high level of ATX in mineralized aortic valves, which colocalized with oxidized phospholipids and apolipoprotein(a). We detected a high level of ATX activity in the Lp(a) fraction in circulation. Interaction between ATX and Lp(a) was confirmed by in situ proximity ligation assay. Moreover, we documented that valve interstitial cells also expressed ATX in CAVD. We showed that ATX-lysophosphatidic acid promotes the mineralization of the aortic valve through a nuclear factor κB/interleukin 6/bone morphogenetic protein pathway. In LDLR(-/-)/ApoB(100/100)/IGFII mice, ATX is overexpressed and lysophosphatidic acid promotes a strong deposition of hydroxyapatite of calcium in aortic valve leaflets and accelerates the development of CAVD.
CONCLUSIONS: ATX is transported in the aortic valve by Lp(a) and is also secreted by valve interstitial cells. ATX-lysophosphatidic acid promotes inflammation and mineralization of the aortic valve and thus could represent a novel therapeutic target in CAVD.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  ENPP2; aortic stenosis, calcific; aortic valve stenosis; autotaxin; calcific aortic valve disease; lipoprotein(a); lipoproteins; lysophosphatidic acid; lysophosphatidylcholine

Mesh:

Substances:

Year:  2015        PMID: 26224810     DOI: 10.1161/CIRCULATIONAHA.115.016757

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  70 in total

1.  Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis.

Authors:  Rihab Bouchareb; Marie-Chloé Boulanger; Lionel Tastet; Ghada Mkannez; Mohamed J Nsaibia; Fayez Hadji; Abdellaziz Dahou; Younes Messadeq; Benoit J Arsenault; Philippe Pibarot; Yohan Bossé; André Marette; Patrick Mathieu
Journal:  Eur Heart J       Date:  2019-05-01       Impact factor: 29.983

2.  Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.

Authors:  Michael B Boffa; Tanya T Marar; Calvin Yeang; Nicholas J Viney; Shuting Xia; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2019-09-24       Impact factor: 5.922

3.  A Rock and a Hard Place: Chiseling Away at the Multiple Mechanisms of Aortic Stenosis.

Authors:  Elena Aikawa; Peter Libby
Journal:  Circulation       Date:  2017-05-16       Impact factor: 29.690

4.  Effects of diet and hyperlipidemia on levels and distribution of circulating lysophosphatidic acid.

Authors:  Maria P Kraemer; Guogen Mao; Courtney Hammill; Baoxiang Yan; Yu Li; Fredrick Onono; Susan S Smyth; Andrew J Morris
Journal:  J Lipid Res       Date:  2019-09-04       Impact factor: 5.922

5.  DNA methylation of a PLPP3 MIR transposon-based enhancer promotes an osteogenic programme in calcific aortic valve disease.

Authors:  Ghada Mkannez; Valérie Gagné-Ouellet; Mohamed Jalloul Nsaibia; Marie-Chloé Boulanger; Mickael Rosa; Deborah Argaud; Fayez Hadji; Nathalie Gaudreault; Gabrielle Rhéaume; Luigi Bouchard; Yohan Bossé; Patrick Mathieu
Journal:  Cardiovasc Res       Date:  2018-09-01       Impact factor: 10.787

6.  Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis.

Authors:  Teresa Trenkwalder; Christopher P Nelson; Muntaser D Musameh; Ify R Mordi; Thorsten Kessler; Costanza Pellegrini; Radoslaw Debiec; Tobias Rheude; Viktor Lazovic; Lingyao Zeng; Andreas Martinsson; J Gustav Smith; Jesper R Gådin; Anders Franco-Cereceda; Per Eriksson; Jonas B Nielsen; Sarah E Graham; Cristen J Willer; Kristian Hveem; Adnan Kastrati; Peter S Braund; Colin N A Palmer; Amparo Aracil; Oliver Husser; Wolfgang Koenig; Heribert Schunkert; Chim C Lang; Christian Hengstenberg; Nilesh J Samani
Journal:  Int J Cardiol       Date:  2018-11-17       Impact factor: 4.164

Review 7.  Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis.

Authors:  Sotirios Tsimikas
Journal:  Circ Res       Date:  2019-02       Impact factor: 17.367

8.  Bone Morphogenetic Protein Signaling Is Required for Aortic Valve Calcification.

Authors:  M Victoria Gomez-Stallons; Elaine E Wirrig-Schwendeman; Keira R Hassel; Simon J Conway; Katherine E Yutzey
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-05-19       Impact factor: 8.311

9.  A Not-So-Little Role for Lipoprotein(a) in the Development of Calcific Aortic Valve Disease.

Authors:  Maximillian A Rogers; Elena Aikawa
Journal:  Circulation       Date:  2015-07-29       Impact factor: 29.690

Review 10.  Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.

Authors:  Calvin Yeang; Michael J Wilkinson; Sotirios Tsimikas
Journal:  Curr Opin Cardiol       Date:  2016-07       Impact factor: 2.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.